MEMORANDUM AND ORDER Plaintiff Maria Gioia (“plaintiff”), acting pro se, commenced this diversity action on March 1, 2021 by filing an amended complaint against Janssen Pharmaceuticals (“defendant” or “Janssen”), manufacturers of the drug Invega. (Am. Compl., ECF No. 33.)1 Plaintiff alleges that she suffered injuries because the defendant failed to properly warn of Invega’s side effects. (Id.) Before the Court is defendant’s motion to dismiss the amended complaint pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure. (Def.’s Mot. to Dismiss, ECF No. 43.) For the reasons discussed below, defendant’s motion is GRANTED. I. BACKGROUND A. Procedural Background Plaintiff commenced product liability actions on August 7, 2019 in Supreme Court, County of Nassau (19-CV-04629, “Gioia I”), and August 29, 2019 in Supreme Court, County of Suffolk (19-CV-05377, “Gioia II”) against Janssen alleging lack of informed consent and failure to warn claims. Defendant removed Gioia I and Gioia II to this Court on the basis of diversity jurisdiction, pursuant to 42 U.S.C. §1332, on August 12, 2019 and September 20, 2019, respectively. (Gioia I, Notice of Removal, ECF No. 1; Gioia II, Notice of Removal, ECF No. 1.) On February 16, 2021, this Court granted defendant’s motion to dismiss plaintiff’s lack of informed consent claim with prejudice and plaintiff’s failure to warn claim without prejudice, granting plaintiff thirty days to amend the complaint. (“Dismissal Order,” ECF No. 32.) On March 1, 2021, plaintiff filed an unsigned amended complaint with exhibits. (Am. Compl.) On March 3, 2021, the clerk’s office directed plaintiff to refile a signed copy of her amended complaint within fourteen days. (ECF No. 34.) Plaintiff refiled her signed amended complaint without exhibits on March 10, 2021. (ECF No. 35.) On April 30, 2021, defendant filed a fully briefed motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6). (ECF Nos. 43-47.) On May 11, 2021, plaintiff filed an addendum to her opposition to defendant’s motion to dismiss. (ECF No. 48.) B. Factual Background2 Plaintiff’s amended complaint alleges that defendant’s failure to warn about the possible side effects of Invega led to her poor performance on medical board examinations and her ultimate ineligibility for a medical residency program. (Am. Compl.
1-3.) Plaintiff alleges that she suffers from subclinical hypothyroidism, Horner’s syndrome, facial nerve damage, motor tics, vocal tics, memory issues, confusion, loss of taste sensation and other feelings, PTSD, peripheral neuropathy, and metabolic syndrome, including hypertension, diabetes, and stroke. (Id.
